A recent study published in The Lancet Infectious Diseases journal revealed that the use of metformin, a widely available and low-cost diabetes medication, reduces the risk of developing long COVID by 41 percent.
Ivermectin, another drug that has been the subject of much debate and scrutiny, showed no significant impact on the incidence of long COVID.
Deep Dive Into the Study
The University of Minnesota spearheaded a large-scale, placebo-controlled study called COVID-OUT. The study aimed to determine whether administering metformin, ivermectin, or fluvoxamine during the early stages of COVID-19 outpatient treatment could decrease the likelihood of developing long COVID.
Sheramy Tsai
Author
Sheramy Tsai, BSN, RN, is a seasoned nurse with a decade-long writing career. An alum of Middlebury College and Johns Hopkins, Tsai combines her writing and nursing expertise to deliver impactful content. Living in Vermont, she balances her professional life with sustainable living and raising three children.
